AMPK activation has been reported to mediate tumor cell migration [ 4, 29].
It has been suggested that variant forms of CD44, especially CD44v6 which is transiently expressed during embryonic lung development, mediates tumor cell migration and invasion and can suffice for a CSC marker [43].
Accumulating evidence has demonstrated that MSCs play complicated roles in tumor development and progression, by increasing stemness of tumor cells, mediating tumor cell migration, promoting angiogenesis, supporting immune responses, and inducing drug resistance [ 9, 10].
Specifically, the delineation of several signaling pathways that mediate tumor cell development, growth, survival, migration, and drug resistance in the BM milieu has helped to identify and validate new targeted therapies, including bortezomib and lenalidomide.
The majority of cancer-related PTPRT mutations affects the extracellular domain that mediates homophilic cell cell interactions, suggesting that mutation of this phosphatase supports tumor migration [ 159].
Membrane type-1 matrix metalloproteinase (MT1-MMP) is a protease activating MMP-2 that mediates cleavage of extracellular matrix components and plays pivotal roles in tumor migration, invasion and metastasis.
In summary, we have applied a novel, functional proteomic approach to identify proteins that mediate tumor cell invasion and have identified a novel role for CD155 in regulating cancer cell invasion and migration.
Mounting evidence indicates that CD4+ T cells can mediate tumor destruction through multiple mechanisms.
Moreover, SKOV3 cell adhesion and migration were decreased after knocking down CD44v6 expression by siRNA, indicating that CD44v6 may play a role in mediating tumor cell adhesion and migration during the metastasis process.
Finally, CD44v6 may play a role in ovarian cancer metastasis by mediating tumor cell adhesion and migration.
